
Scott H. Kollins, PhD received his undergraduate degree in psychology from Duke and his Master’s and Doctorate degrees in Clinical Psychology from Auburn University. After completing his clinical internship at the University of Mississippi Medical Center, where he served as Chief Intern, he joined the faculty of the Department of Psychology at Western Michigan University for three years, before joining the Duke faculty in 2000. Dr. Kollins has published more than 125 scientific papers in peer-reviewed journals. Over the past 10 years, his research has been supported by 6 different federal agencies, including NICHD, NIDA, NIMH, NIEHS, NINDS, and EPA, and he currently holds a mid-career K24 award from NIDA. He has also served as PI on more than 40 industry-funded clinical trials and is a consultant to a number of pharmaceutical companies in the area of ADHD clinical psychopharmacology. He has served as a standing member of the Child Psychopathology and Developmental Disabilities study section and also served as an ad-hoc reviewer for 10 additional NIH study sections and 7 international granting agencies. He is an Associate Editor for the Journal of Attention Disorders and has reviewed for more than 50 different peer-reviewed journals. He is an elected member of the College on Problems of Drug Dependence and the American College of Neuropsychopharmacology. Dr. Kollins is a licensed clinical psychologist and maintains a practice through the ADHD Program’s outpatient clinic. His research interests are in the areas of psychopharmacology and the intersection of ADHD and substance abuse, particularly cigarette smoking.
Education and Training
- Ph.D., Auburn University, 1997
In the News
- Harnessing the Power of Machine Learning for Earlier Autism DiagnosisDecember 9, 2019
- Exposure to Cannabis Alters Your SpermDecember 19, 2018
- Study Suggests Digital Treatment Through a Video Game Could Improve Attention in ADHDDecember 7, 2017
- Duke Receives $12.5 Million to Study Children With Autism and ADHDSeptember 7, 2017
- ADHD Treatment Associated with Lower Smoking RatesMay 13, 2014
- ADHD drugs not linked to increased tobacco useMay 12, 2014
Selected Grants
- Duke Center for ADHD in Girls/Women
- Duke Women's Reproductive Health Research Scholars
- Novel Approaches to Infant Screening for ASD in Pediatric Primary Care
- Unified Program for Therapeutics in Children
- Scalable Computational Platform For Active Closed-Loop Behavioral Coding in Autism Spectrum Disorder
- Duke CTSA (TL1)
- Dyanavel Safety Study
- Co-occurring ADHD in young children with ASD: Precursors, detection, neural signatures, and early treatment
- Mobile health interventions for varenicline adherence among HIV-positive smokers
- Targeting reward dysfunction as a mechanism to improve smoking cessation
- Dyanavel Efficacy Study
- Sleep Dysfunction and Neurocognitive Outcomes in Adolescent ADHD
- Treating Pain in Fibromyalgia
- Maternal obesity, child executive functions and child weight gain
- Increasing Motivation in ADHD Via Self-activation of VTA
- Smoking/Nicotine Dependence in Attention Deficit Hyperactivity Disorder (ADHD)
- Modeling the Neurobehavioral Basis of Extrinsic and Volitional Motivation in ADHD
- Paternal Transgenerational Epigenetic Legacy from Use of Cannabis
- Reactions to Reduced Nicotine Cigarettes in Young Adult Low-Frequency Smokers
- A randomized, sham-controlled, crossover study to evaluate the effects of noise cancelling headphones on neurocognitive and academic outcomes in children and adolescents diagnosed with ADHD
- Effects of Nicotine Reduction on Smoking Behavior in ADHD Smokers
- A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled, Parallel Laboratory Classroom Study with KP415 in Children with Attention-Deficit/Hyperactivity Disorder
- A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years Diagnosed with Attention-deficit/Hyperactivity Disorder
- mSMART: Mobile App based Personalized Solutions and Tools for Medication Adherence of Rx Pills
- Protecting Neurodevelopment in Latino Migrant Children by Reduced Exposure to Organophosphate Pesticides
- RP-BP-EF004: A 12-Month Open Label Safety Study of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR) in Children Ages 4-5 Years Diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD)
- Behavioral and genetic mechanisms of smoking risk in individuals with ADHD
- Smoking Abstinence in ADHD and non-ADHD Smokers: Assessing the Role of Emotion Dysregulation
- A Pharmacokinetic Study of Aptensio XR¿ (Methylphenidate Hydrochloride) Extended-Release capsules in Male or Female Pre-School Children 4 to Under 6 years of age with ADHD in Fed Condition
- RP-BP-EF003: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Titration Study of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR®) in Children Ages 4 to Under 6 Years Diagnosed with ADHD
- Characterizing ADHD using a behavioral model of dopamine function
- Pilot Project: Effects of Cannabis on the Epigenome of Humans and Rats
- A Phase 2, Open-label, Multicenter, Exploratory Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children Aged 4-5 Years with Attention Deficit/Hyperactivity Disorder
- mGluR Mutations in ADHD
- A 6-week, Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group Efficacy and Safety Study of Dasotraline versus Placebo in Subjects 6 to 12 Years of Age with Attention Deficit Hyperactivity Disorder (ADHD)
- A Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group, Efficacy and Safety Study of 2 Doses of Dasotraline in Adults with Attention Deficit Hyperactivity Disorder (ADHD)
- A Ph. 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Safety & Efficacy of Evening-dosed HLD200, a Novel Delayed & ER Formulation (DELEXIS) of Methylphenidate Hydrochloride, on Post waking, Early Mor
- An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
- SEP-225289 in Adults with Attention Deficit Hyperactivity Disorder (ADHD)
- A Phase IIb, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Crossover, Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults with Attention-Deficit Hyperactivity Disorder (ADHD)
- A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled, Crossover Study to Evaluate the Efficacy of AR11 (Amphetamine Sulfate) in Pediatric Patients (Ages 6-12) with ADHD in a Laboratory Classroom
- A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Evaluation of Single Oral Doses of SEP-225289 in Subjects 6 to 17 Years of Age with Attention Deficit Hyperactivity Disorder
- A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-ARM, MULTI-CENTER STUDY MEASURING THE EFFICACY AND SAFETY OF PRC-063 IN ADOLESCENT ADHD PATIENTS
- A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-ARM, MULTI-CENTER STUDY MEASURING THE EFFICACY AND SAFETY OF PRC-063 IN ADULT ADHD PATIENTS
- A SIX-MONTH, OPEN-LABEL, MULTI-CENTER STUDY OF THE SAFETY AND EFFICACY OF PRC-063 IN ADULTS AND ADOLESCENTS WITH ADHD
- A Phase III Clinical Endpoint Evaluation Study Examining the Safety and Efficacy of HLD200 in Pediatric Subjects with Attention-Deficit Hyperactivity Disorder (CEES ADHD)
- A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared with Placebo in Adults with Attention Deficit/Hyperactivity Disorder (ADHD)
- Amphetamine Extended-Release Oral Suspension in the Treatment of Children with ADHD: A Laboratory School Study
- Project 1: Evaluating New Nicotine Standards in Cigarettes - Supplement
- Elucidating links between ADHD symptoms and tobacco/alcohol use trajectories
- Neuropharmacology of Response Inhibition in Comorbid ADHD and Nicotine Dependence
- A randomized, multicenter, double-blind, placebo-controlled, parallel group study of NT0102 Methylphenidate Polistirex Extended-Release Oral Disintegrating Tablets in children w/ADHD
- Sensitivity to smoking reinforcement in women: menstrual cycle effects
- Ecological Momentary Assessment of Ad Lib Smoking in ADHD Smokers
- Genetic basis of smoking abstinence, smoking reinforcement, and inhibitory control
- Smoking reinforcement in adults with and without ADHD
- Follow up of the PATS sample
- Candidate Gene Analysis of Persistent AD/HD
- Mechanisms of Nicotine Dependence in ADHD Adults
- Development of Behavorial Screening Tools for ADHD
- Methylphenidate Abuse Potential in ADHD Adults
- Functional Neuroanatomical Deficits in ADHD Families
- Attention Deficit Hyperactivity Disorder